Frontlight ResearchEarly access
CompletedPhase 2
Leniolisib for Immune Dysregulation in PIDs
Key facts
- Who runs it
- Pharming Technologies B.V.
- Where
- Bethesda, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 13 people enrolled
- Started
- 21 Oct 2024
- Ended
- 23 Jun 2026
- Type of study
- Interventional
- Treatments tested
- Leniolisib
- Record updated
- 19 October 2026
Who can take part
- Age
- 12 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Subjects 12 to 75 years of age
- Diagnosed with a PID due to disease-causing pathogenic or likely pathogenic variant(s) in the following genes: SOCS1, PTEN, CTLA4, NFKB1 (only those variants leading to NFKB pathway activation), or FAS (germline or somatic), or diagnosed with RAS associated leukoproliferative disorder (and not juvenile myelomonocytic leukemia [JMML]) due to somatic variants in NRAS or KRAS
- Subjects must have 1 or more of the following:; One or more blood cytopenias related to the underlying PID defined as hemoglobin <10 g/dL, platelet count <100,000/µL, or neutrophil count <1000/µL; Splenomegaly evident by CT imaging with craniocaudal spleen measurement >10 cm; Lymphadenopathy evident by CT imaging with at least 1 measurable index lymph node (long axis >1.5 cm) as per Cheson methodology; GLILD or other PID-related ILD with quantifiable CT chest imaging findings evident on baseline CT scan
- At screening, vital signs; Systolic blood pressure 80-139 mm Hg; Diastolic blood pressure 50-89 mm Hg; Pulse rate 50-110 bpm; Oxygen saturation 93-100%
- Subjects or their legal representatives (for subjects under the age of 18 years) must be able to provide written informed consent
Who cannot take part
- Subject has had a successful hematopoietic stem-cell transplant (HSCT)
- Previous or concurrent use of immunosuppressive medication, such as:; Use of an mTOR inhibitor or a PI3Kδ inhibitor within 3 weeks prior to first dosing ; Rituximab or other B-cell depleting antibodies, belimumab, cyclophosphamide, or alemtuzumab within 6 months prior to first dosing; Cyclosporine A, mycophenolate mofetil, 6-mercaptopurine, azathioprine, methotrexate, tacrolimus, ruxolitinib, or other JAK inhibitors within 3 weeks prior to first dosing; Corticosteroids above 25 mg prednisone or equivalent per day within 2 weeks prior to first dosing; Other immunosuppressive agents expected to have a significant impact on immune cell number or function; Abatacept is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months prior to first dosing
- Subject is receiving concurrent treatment with another investigational therapy or use of another investigational therapy less than 4 weeks or 5 half-lives (whichever is longer) prior to first dosing
- Current use of medication known to be a strong inhibitor, or moderate or strong inducer, of isoenzyme P450 CYP3A
- Current use of medications that act as BCRP, OATP1B1, and OATP1B3 substrates
- Administration of live vaccines starting from 6 weeks before first dose of study medication
- Subject has a previous diagnosis of lymphoma within 1 year of the first dose of study medication
- Donation or loss of 400 mL or more of blood within 8 weeks before the first dose
- Subject has had major surgery requiring hospitalization or radiotherapy within 4 weeks prior to the first dose or has a planned or expected major surgical procedure during the study period
- History of hypersensitivity to the study drug or to drugs of similar chemical classes
- History of acquired immunodeficiency diseases, including a positive HIV test result at screening
- Uncontrolled chronic or recurrent infectious disease (except those considered to be characteristic of a PID) or evidence of tuberculosis infection
- Any surgical or medical condition which may jeopardize the subject in case of participation in the study, or might significantly alter the absorption, distribution, metabolism, or excretion of drugs
- A positive hepatitis B surface antigen, positive hepatitis B PCR, positive hepatitis C PCR, or positive hepatitis C antibody result at screening
- Subject has a history of malignancy (except lymphoma) within 3 years before the first dose of study medication, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix
- Subject has uncontrolled post-transplant lymphoproliferative disease (PTLD)-like EBV related lymphoproliferative disease
- Subject has a history or current electrocardiogram (ECG) abnormalities indicating a significant risk of safety for subjects participating in the study
- Pregnant or nursing (lactating) individuals,
- Individuals of child-bearing potential, unless they are using highly effective methods of contraception
Where in United States
- National Institute Of HealthBethesda, United States
About the trial
What the trial wants to find out
This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib. Secondary objectives include assessments of PK/PD, and to explore clinical efficacy measures with administration of three different dose levels of leniolisib.
The group in the trial
- LeniolisibTreatment being tested
All subjects participating will receive Leniolisib film-coated tablets (FCTs) at a starting dose of 10 mg BID for 4 weeks, followed by 30 mg BID for 4 weeks, and then 70 mg BID for 12 weeks.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders
- Publications
- Leniolisib reduced lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome.Journal of human immunity, 2026
- Record updated
- 19 October 2026